Please wait while we load the requested 10-Q report or click the link below:
NPS Pharma Reports Third-Quarter 2014 Financial Results
Net global Gattex®/Revestive® sales of $28 million representing sequential growth of 28 percent
Company on track to meet full-year financial guidance
Commercial-readiness activities continue in advance of Natpara’s January 24 PDUFA date
Conference call today at 4:30 PM ET
BEDMINSTER, N.J.--(BUSINESS WIRE)--November 10, 2014--NPS Pharmaceuticals, Inc. (NASDAQ:NPSP), a global biopharmaceutical company pioneering and delivering innovative therapies that transform the lives of patients with rare diseases, today reported its results for the quarter ended September 30, 2014.
NPS Pharma reported net global Gattex®/Revestive® sales of $28.1 million for the third quarter of 2014, compared to $11.0 million for the same period last year. Based on the company’s expectations for the remainder of 2014, NPS Pharma currently anticipates its full-year net sales will be in the lower end of its guidance range of $100 and $110 million.
“We are pleased with the continued success of Gattex/Revestive, which has achieved $68 million of net sales so far this year leaving us on track to deliver more than 200% year-over-year growth,” said Francois Nader, MD, president and chief executive officer of NPS Pharma. “We continue to identify new Short Bowel Syndrome patients and grow our prescriber base leaving us confident in the long-term outlook for Gattex. Internationally, we are also making important progress. Revestive is now officially launched in Germany and we filed for orphan drug designation in Japan.”
Dr. Nader added: “We were very gratified to receive a positive Advisory Committee vote recommending the approval of Natpara for the long-term treatment of hypoparathyroidism. We are working with the FDA to finalize our label and Risk Evaluation and Mitigation Strategy. In parallel, we are advancing a number of pre-commercial activities to prepare for the successful launch of Natpara in the second quarter of 2015.”
The following information was filed by Nps Pharmaceuticals Inc (NPSP) on Monday, November 10, 2014 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-Q Quarterly Report statement of earnings and operation as management may choose to highlight particular information in the press release.
View differences made from one quarter to another to evaluate Nps Pharmaceuticals Inc's financial trajectory
Compare this 10-Q Quarterly Report to its predecessor by reading our highlights to see what text and tables were
removed , and by Nps Pharmaceuticals Inc.